Vemurafenib en el tratamiento de glioblastoma con mutación BRAF V600: a propósito de un caso

IF 1.3 Q4 PHARMACOLOGY & PHARMACY

FARMACIA HOSPITALARIA Pub Date : 2025-09-01 DOI:10.1016/j.farma.2025.03.013

Irene de la Fuente Villaverde , Alicia Caso González , Mónica Carbajales Álvarez , Alba Martínez Torrón , Sergio Fernández Lastras , Juan Luis García Llano , Ana Lozano Blázquez

{"title":"Vemurafenib en el tratamiento de glioblastoma con mutación BRAF V600: a propósito de un caso","authors":"Irene de la Fuente Villaverde , Alicia Caso González , Mónica Carbajales Álvarez , Alba Martínez Torrón , Sergio Fernández Lastras , Juan Luis García Llano , Ana Lozano Blázquez","doi":"10.1016/j.farma.2025.03.013","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>Glioblastoma is one of the most aggressive primary brain tumors with the worst prognosis. Few therapeutic options are currently available. Vemurafenib is a kinase inhibitor that demonstrated efficacy in clinical trials for the treatment of tumors with <em>BRAF</em> V600 mutation. Its experience of use in glioblastomas is very limited.</div><div>We present the case of a patient diagnosed with BRAF V600 mutated glioblastoma who progressed to standard therapy. After starting treatment with vemurafenib in June 2022, the patient currently maintains a good clinical situation and the disease remains stable, with no progression observed.</div></div><div><h3>Discussion</h3><div>There is little literature supporting the efficacy of vemurafenib in BRAF 600 mutated glioblastomas. Published data suggest promising results, although survival in these patients remains low. This patient's progression-free survival is one of the longest documented to date.</div></div>","PeriodicalId":45860,"journal":{"name":"FARMACIA HOSPITALARIA","volume":"49 5","pages":"Pages 346-348"},"PeriodicalIF":1.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"FARMACIA HOSPITALARIA","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1130634325000388","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

Glioblastoma is one of the most aggressive primary brain tumors with the worst prognosis. Few therapeutic options are currently available. Vemurafenib is a kinase inhibitor that demonstrated efficacy in clinical trials for the treatment of tumors with BRAF V600 mutation. Its experience of use in glioblastomas is very limited.

We present the case of a patient diagnosed with BRAF V600 mutated glioblastoma who progressed to standard therapy. After starting treatment with vemurafenib in June 2022, the patient currently maintains a good clinical situation and the disease remains stable, with no progression observed.

Discussion

There is little literature supporting the efficacy of vemurafenib in BRAF 600 mutated glioblastomas. Published data suggest promising results, although survival in these patients remains low. This patient's progression-free survival is one of the longest documented to date.

查看原文本刊更多论文

Vemurafenib治疗BRAF V600突变胶质母细胞瘤1例

胶质母细胞瘤是一种侵袭性最强、预后最差的原发性脑肿瘤。目前可供选择的治疗方法很少。Vemurafenib是一种激酶抑制剂，在临床试验中显示出治疗BRAF V600突变肿瘤的疗效。它在胶质母细胞瘤中的应用经验非常有限。我们提出的病例患者诊断为BRAF V600突变胶质母细胞瘤谁进展到标准治疗。患者于2022年6月开始使用vemurafenib治疗后，目前临床情况良好，病情稳定，未见进展。讨论：很少有文献支持vemurafenib治疗BRAF 600突变胶质母细胞瘤的疗效。已发表的数据显示了令人鼓舞的结果，尽管这些患者的生存率仍然很低。该患者的无进展生存期是迄今为止记录的最长的患者之一。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

FARMACIA HOSPITALARIA PHARMACOLOGY & PHARMACY-

CiteScore

1.90

自引率

21.40%

发文量

审稿时长

37 days

期刊介绍： Una gran revista para acceder a los mejores artículos originales y revisiones de la farmacoterapia actual. Además, es Órgano de expresión científica de la Sociedad Española de Farmacia Hospitalaria, y está indexada en Index Medicus/Medline, EMBASE/Excerpta Médica, Alert, Internacional Pharmaceutical Abstracts y SCOPUS.